The Ministry of Health announces that from 13 May 2022, the pharmaceutical product Paxlovid (PF-07321332 150 mg/ ritonavir 100 mg) coated tablets will be available for prescription through the GHS IT system to patients with laboratory-confirmed (PCR or Rapid Ag Test) mild or moderate COVID-19 disease, who do not require hospitalization for severe or critical COVID-19 disease, within 5 days of the date of onset of symptoms or date of test (whichever occurs first) and with at least one risk factor.
Before prescribing, treating physicians will be asked to answer a questionnaire that will be posted on the GHS IT system to ensure that prescribing will only be done for patients who meet the criteria set by the ad-hoc committee of the Ministry of Health for the creation and implementation of the relevant protocols related to COVID-19 medication.
The prescription of Paxlovid will be available from the following physicians:
- Adult Personal Physicians
- Internists
- Physicians with Specialization in Infectious Diseases
- Pulmonologists
- Hematologists
- Physicians with Specialization in Infectious Diseases- Oncologists
- Cardiologists
- Nephrologists
- Neurologists
- Neurologists
- Rheumatologists
- Endocrinologists
- Geriatricians
- Gastroenterologists
- Oncologists-Radiotherapists
The pharmaceutical product Paxlovid will be available only from the following hospital pharmacies of OKYPY: Nicosia, Limassol, Limassol, Larnaca, Famagusta, Pafos General Hospitals and Troodos and Polos Chrysochous Hospitals.
It should also be noted that a supplement (1€) should NOT be collected for the medicinal product Paxlovid.
Important information about Paxlovid:
The medicinal product Paxlovid is authorised by the European Medicines Agency (EMA).
You are required to consult the Summary of Product Characteristics (SmPC) regarding contraindications, special warnings/precautions and interactions of Paxlovid with other medicinal products.
The SmPC and all relevant product information is available at the following link: https:/www.ema.europa.eu/en/medicines/human/EPAR/paxlovid#product-information-section
Reporting of suspected adverse reactions with the drug Paxlovid
Healthcare professionals are asked to report any suspected adverse reactions through the national reporting system to the Department of Health's Pharmaceutical Services by electronic submission at the link Yellow Card or to the following contact details:
Pharmaceutical Services
Ministry of Health
CY-1475 Nicosia
Tel: +357 22608607
Fax: + 357 22608669
Website: www.moh.gov.cy/phs
(AF)
Contents of this article including associated images are belongs PIO
Views & opinions expressed are those of the author and/or PIO
Source
